To use all functions of this page, please activate cookies in your browser.
my.chemeurope.com
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Benserazide
Benserazide is an inhibitor of DOPA decarboxylase that does not enter the central nervous system. It is often given in combination with L-DOPA (levodopa) as Co-Beneldopa (BAN) (e.g. Madopar® by Roche in UK) in the treatment of Parkinson's disease to prevent the conversion of L-DOPA to dopamine in the periphery (due to its molecular size it can not penetrate the blood brain barrier) the amount that reaches the central nervous system and reducing the required dose, and also decreasing side effects due to the presence of dopamine in the system (outside of the central nervous system). It has no antiparkinson actions when given alone. Additional recommended knowledge
|
||||||||||||||||||||||||||||||||||||||||
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Benserazide". A list of authors is available in Wikipedia. |